Stephane Bancel - 24 Nov 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Executive Officer, Director
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
24 Nov 2021
Net transactions value
-$2,457,090
Form type
4
Filing time
26 Nov 2021, 12:59:38 UTC
Previous filing
19 Nov 2021
Next filing
30 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale $2,457,090 -9,000 -0.15% $273.01 5,940,868 24 Nov 2021 Direct F1
transaction MRNA Common Stock Gift -4,000 -0.07% 5,936,868 24 Nov 2021 Direct F2, F3
holding MRNA Common Stock 9,050,372 24 Nov 2021 See Footnote F4
holding MRNA Common Stock 7,144,880 24 Nov 2021 See Footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.
F2 The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 13, 2021.
F3 The reported disposition represents a bona fide charitable gift made by the reporting person.
F4 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F5 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.